Document text
Principal Investigator: Babafemi O Taiwo
Organization: NORTHWESTERN UNIVERSITY AT CHICAGO
Fiscal Year: 2020
Award: $814,136
Funding agency: National Institute of Allergy and Infectious Diseases
Parent Award Project Summary
The Chicago Clinical Trials Unit (CCTU) is a consortium of five Clinical Research Sites (CRSs) which will
address three priority clinical research areas of the NIAID: 1) adult HIV therapeutic strategies including HIV
cure, noninfectious comorbidities, and infectious co-morbidities of hepatitis and tuberculosis; 2) vaccines to
prevent HIV; and 3) integrated HIV prevention strategies. The CCTU consists of five highly experienced and
scientifically productive CRSs that are uniquely positioned to develop, implement and adapt the clinical
research priorities of the NIAID clinical research priority areas. The CCTU has a proven track record and will
continue its productivity through active engagement with a diverse host of at risk and HIV-impacted
communities, participation in high impact, ground-breaking clinical research studies, efficient management of
resources and critical performance oversight of the clinical activities, laboratories, and pharmacies. The CCTU
includes CRSs and personnel that have long term and productive involvement with three of the research
networks; the fourth-antibacterial resistance-being a new network in this consortium. The CRSs and their
network affiliations include: Northwestern University (adult HIV therapeutic strategies); University of Illinois
Chicago (vaccines to prevent HIV, integrated HIV prevention), Rush University (adult HIV therapeutic
strategies), University of Chicago (integrated HIV prevention strategies) and Trinity Health & Wellness Center
(adult HIV therapeutic strategies). Four of the CRSs are located in Chicago, an ethnically and racially diverse
urban area of 9.5 million persons that is the third largest metropolitan region in the United States and one of
the major urban HIV epicenters. The aims of this proposal are: development, implementation and adaptation of
the clinical research program of the 1) Adult HIV Therapeutics Strategy Network, 2) the Vaccines to Prevent
HIV Network, 3) the Integrated HIV Prevention Strategies Network, and 4) Bidirectional engagement of the
relevant and at risk HIV-infected/impacted communities with the CCTU clinical researchers. The CCTU is well
positioned to reach diverse populations and contribute significantly to the NIAID research agenda.
Terms: <2019 novel coronavirus><2019-nCoV><21+ years old><AIDS Virus><AIDS prevention><AIDS/HIV><AIDS/HIV problem><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome Virus><Address><Adult><Adult Human><Antibacterial Drug Resistance><Antibacterial Drug Resistant><Antibacterial resistant><Area><Award><Bacterial Drug Resistance><Chicago><Clinical><Clinical Research><Clinical Study><Clinical Trials Unit><Communities><Community Participation><Development><HIV><HIV Prevention><HIV/AIDS><HIV/AIDS prevention><HIV/AIDS problem><Health><Hepatitis><Human Immunodeficiency Viruses><Human Resources><Illinois><Investigators><LAV-HTLV-III><Laboratories><Lymphadenopathy-Associated Virus><M tuberculosis infection><M. tb infection><M. tuberculosis infection><M.tb infection><M.tuberculosis infection><MTB infection><Manpower><Mycobacterium tuberculosis (MTB) infection><Mycobacterium tuberculosis infection><NIAID><National Institute of Allergy and Infectious Disease><Parents><Performance><Persons><Pharmacies><Pharmacy facility><Population Heterogeneity><Position><Positioning Attribute><Preventative strategy><Prevention><Prevention strategy><Preventive strategy><Productivity><Research><Research Personnel><Research Priority><Research Resources><Researchers><Resources><Risk><SARS-CoV-2><SARS-CoV2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related coronavirus 2><Scientific Advances and Accomplishments><Severe acute respiratory syndrome coronavirus 2><TB infection><Testing><Therapeutic><Tuberculosis><United States><Universities><Vaccines><Virus-HIV><Wellness Center><Wuhan coronavirus><adulthood><anti-bacterial drug resistance><anti-bacterial drug resistant><anti-bacterial resistance><anti-bacterial resistant><antibacterial resistance><clinical research site><clinical site><co-morbid><co-morbidity><comorbidity><developmental><disseminated TB><disseminated tuberculosis><diverse populations><effective therapy><effective treatment><ethnic diversity><ethnically diverse><experience><heterogeneous population><infection due to Mycobacterium tuberculosis><metropolitan><personnel><population diversity><prevent><preventing><programs><racial diversity><racially diverse><research study><resistance to anti-bacterial><resistance to antibacterial><resistant to anti-bacterial><resistant to antibacterial><scientific accomplishments><scientific advances><treatment strategy><tuberculosis infection><tuberculous spondyloarthropathy><urban area>